FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894119802> ?p ?o ?g. }

• W2894119802 endingPage "832" @default.
• W2894119802 startingPage "826" @default.
• W2894119802 abstract "Objective/backgroundThe development of an abdominal aortic aneurysm (AAA) involves extensive extracellular matrix remodelling, leading to aortic wall weakening. This process is mediated by proteases, including cysteinyl cathepsins. Cystatins are their endogenous inhibitors. This study tested whether plasma cystatin B levels in patients with AAA differed from those of healthy controls.MethodsPlasma samples from patients with AAA and age matched controls were selected from the Viborg Vascular (VIVA) screening trial for AAA. Enzyme linked immunosorbent assay determined plasma cystatin B. T-test, logistic regression, Pearson's correlation and Cox regression tested whether plasma cystatin B correlates with AAA size and growth rate, or serves as a marker for AAA.ResultsPlasma cystatin B levels were significantly higher in patients with AAA than in controls (p < 0.001). Logistic regression analysis showed that cystatin B tertile at baseline was associated with the presence of AAA before (odds ratio [OR] 1.656; p < 0.001) and after adjustment for peripheral arterial disease (PAD), chronic obstructive pulmonary disease (COPD), and previous ischaemic events (OR 1.526; p < 0.001). A t-test showed a significant association between cystatin B and PAD at screening, hospital diagnosis of COPD, previous atherosclerotic events, and use of low dose aspirin. Pearson's correlation test showed positive and significant associations between cystatin B and AAA size (r = 0.15; p < 0.001). Cox regression test showed that plasma cystatin B tertile at baseline was associated with later AAA surgical repair before (hazard ratio [HR] 1.387; p < 0.001) and after adjustment for PAD, COPD, previous ischaemic event, and maximum infrarenal aortic diameter (HR 1.523; p < 0.001).ConclusionIn contrast to prior studies that showed that cystatin C is negatively associated with AAA development, this study demonstrated a positive association between cystatin B and AAA size and associations between cystatin B tertile at baseline and AAA presence and need for later surgical repair. It is possible that these two cystatins inhibit cathepsin activity and participate in AAA with different mechanisms. The development of an abdominal aortic aneurysm (AAA) involves extensive extracellular matrix remodelling, leading to aortic wall weakening. This process is mediated by proteases, including cysteinyl cathepsins. Cystatins are their endogenous inhibitors. This study tested whether plasma cystatin B levels in patients with AAA differed from those of healthy controls. Plasma samples from patients with AAA and age matched controls were selected from the Viborg Vascular (VIVA) screening trial for AAA. Enzyme linked immunosorbent assay determined plasma cystatin B. T-test, logistic regression, Pearson's correlation and Cox regression tested whether plasma cystatin B correlates with AAA size and growth rate, or serves as a marker for AAA. Plasma cystatin B levels were significantly higher in patients with AAA than in controls (p < 0.001). Logistic regression analysis showed that cystatin B tertile at baseline was associated with the presence of AAA before (odds ratio [OR] 1.656; p < 0.001) and after adjustment for peripheral arterial disease (PAD), chronic obstructive pulmonary disease (COPD), and previous ischaemic events (OR 1.526; p < 0.001). A t-test showed a significant association between cystatin B and PAD at screening, hospital diagnosis of COPD, previous atherosclerotic events, and use of low dose aspirin. Pearson's correlation test showed positive and significant associations between cystatin B and AAA size (r = 0.15; p < 0.001). Cox regression test showed that plasma cystatin B tertile at baseline was associated with later AAA surgical repair before (hazard ratio [HR] 1.387; p < 0.001) and after adjustment for PAD, COPD, previous ischaemic event, and maximum infrarenal aortic diameter (HR 1.523; p < 0.001). In contrast to prior studies that showed that cystatin C is negatively associated with AAA development, this study demonstrated a positive association between cystatin B and AAA size and associations between cystatin B tertile at baseline and AAA presence and need for later surgical repair. It is possible that these two cystatins inhibit cathepsin activity and participate in AAA with different mechanisms." @default.
• W2894119802 created "2018-10-05" @default.
• W2894119802 creator A5017768395 @default.
• W2894119802 creator A5025535213 @default.
• W2894119802 creator A5039740503 @default.
• W2894119802 creator A5041382502 @default.
• W2894119802 creator A5087049740 @default.
• W2894119802 date "2018-12-01" @default.
• W2894119802 modified "2023-09-30" @default.
• W2894119802 title "Plasma Cystatin B Association With Abdominal Aortic Aneurysms and Need for Later Surgical Repair: A Sub-study of the VIVA Trial" @default.
• W2894119802 cites W1503915976 @default.
• W2894119802 cites W1582842606 @default.
• W2894119802 cites W1673084462 @default.
• W2894119802 cites W1699719812 @default.
• W2894119802 cites W1977015656 @default.
• W2894119802 cites W1982587620 @default.
• W2894119802 cites W1986316605 @default.
• W2894119802 cites W1995750928 @default.
• W2894119802 cites W1998968358 @default.
• W2894119802 cites W2013133878 @default.
• W2894119802 cites W2013986093 @default.
• W2894119802 cites W2018904798 @default.
• W2894119802 cites W2019736607 @default.
• W2894119802 cites W2021722828 @default.
• W2894119802 cites W2038786203 @default.
• W2894119802 cites W2041817146 @default.
• W2894119802 cites W2042693173 @default.
• W2894119802 cites W2053095426 @default.
• W2894119802 cites W2064777157 @default.
• W2894119802 cites W2091704593 @default.
• W2894119802 cites W2092961096 @default.
• W2894119802 cites W2097698723 @default.
• W2894119802 cites W2106534618 @default.
• W2894119802 cites W2127118146 @default.
• W2894119802 cites W2134704572 @default.
• W2894119802 cites W2149826984 @default.
• W2894119802 cites W2158728905 @default.
• W2894119802 cites W2164795717 @default.
• W2894119802 cites W2168700225 @default.
• W2894119802 cites W2290840312 @default.
• W2894119802 cites W2412315713 @default.
• W2894119802 cites W2415780945 @default.
• W2894119802 cites W2623035054 @default.
• W2894119802 cites W2745813324 @default.
• W2894119802 cites W2762805548 @default.
• W2894119802 cites W2799357439 @default.
• W2894119802 doi "https://doi.org/10.1016/j.ejvs.2018.08.028" @default.
• W2894119802 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6289677" @default.
• W2894119802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30262158" @default.
• W2894119802 hasPublicationYear "2018" @default.
• W2894119802 type Work @default.
• W2894119802 sameAs 2894119802 @default.
• W2894119802 citedByCount "8" @default.
• W2894119802 countsByYear W28941198022018 @default.
• W2894119802 countsByYear W28941198022019 @default.
• W2894119802 countsByYear W28941198022020 @default.
• W2894119802 countsByYear W28941198022021 @default.
• W2894119802 countsByYear W28941198022022 @default.
• W2894119802 crossrefType "journal-article" @default.
• W2894119802 hasAuthorship W2894119802A5017768395 @default.
• W2894119802 hasAuthorship W2894119802A5025535213 @default.
• W2894119802 hasAuthorship W2894119802A5039740503 @default.
• W2894119802 hasAuthorship W2894119802A5041382502 @default.
• W2894119802 hasAuthorship W2894119802A5087049740 @default.
• W2894119802 hasBestOaLocation W28941198021 @default.
• W2894119802 hasConcept C126322002 @default.
• W2894119802 hasConcept C141071460 @default.
• W2894119802 hasConcept C151956035 @default.
• W2894119802 hasConcept C156957248 @default.
• W2894119802 hasConcept C159641895 @default.
• W2894119802 hasConcept C207103383 @default.
• W2894119802 hasConcept C2776098176 @default.
• W2894119802 hasConcept C2776780178 @default.
• W2894119802 hasConcept C2779548226 @default.
• W2894119802 hasConcept C2779993416 @default.
• W2894119802 hasConcept C2780412452 @default.
• W2894119802 hasConcept C44249647 @default.
• W2894119802 hasConcept C71924100 @default.
• W2894119802 hasConcept C90924648 @default.
• W2894119802 hasConceptScore W2894119802C126322002 @default.
• W2894119802 hasConceptScore W2894119802C141071460 @default.
• W2894119802 hasConceptScore W2894119802C151956035 @default.
• W2894119802 hasConceptScore W2894119802C156957248 @default.
• W2894119802 hasConceptScore W2894119802C159641895 @default.
• W2894119802 hasConceptScore W2894119802C207103383 @default.
• W2894119802 hasConceptScore W2894119802C2776098176 @default.
• W2894119802 hasConceptScore W2894119802C2776780178 @default.
• W2894119802 hasConceptScore W2894119802C2779548226 @default.
• W2894119802 hasConceptScore W2894119802C2779993416 @default.
• W2894119802 hasConceptScore W2894119802C2780412452 @default.
• W2894119802 hasConceptScore W2894119802C44249647 @default.
• W2894119802 hasConceptScore W2894119802C71924100 @default.
• W2894119802 hasConceptScore W2894119802C90924648 @default.
• W2894119802 hasFunder F4320306230 @default.
• W2894119802 hasFunder F4320321001 @default.
• W2894119802 hasFunder F4320322766 @default.
• W2894119802 hasFunder F4320332161 @default.
• W2894119802 hasIssue "6" @default.

• next